Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 6 months to 18 years~* Children presenting to RCH ED with moderate/severe cellulitis~* Moderate/severe: defined in this study, as those assessed by ED clinician to need IV antibiotics~* Reasons for starting IV antibiotics include:~  1. Failed oral therapy (not improving despite 24h of oral therapy)~ 2. Rapidly spreading redness (from patient/parent history)~ 3. Significant swelling/redness/pain~ 4. Systemic symptoms/signs (eg. fever, lethargy)~ 5. Difficult to treat areas (eg. face, ear, toe)~Exclusion Criteria:~Children will be excluded:~1. With orbital cellulitis or unable to exclude orbital cellulitis,~2. With penetrating injury/bites,~3. With suspected fasciitis or myositis,~4. With toxicity: tachycardia when afebrile or hypotension (both as per the limits set out by RCH Resuscitation Card), poor central perfusion (capillary refill \>2 seconds)~5. With immunosuppression,~6. With varicella,~7. With suspected/confirmed foreign body,~8. With abscess not drained,~9. With dental abscess,~10. With concurrent sinusitis or otitis media or lymphadenitis necessitating different antibiotic treatment to flucloxacillin monotherapy or ceftriaxone monotherapy,~11. With liver co-morbidities~12. With other medical diagnoses warranting admission to hospital for observation or treatment relating to the known medical condition~13. With difficult intravenous access,~14. Age \<6 months old,~15. Who could be managed on oral antibiotics (ie assessed as mild cellulitis)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Home (Type: EXPERIMENTAL): Patients will be treated at home through the Hospital-In-The-Home program with intravenous once daily ceftriaxone (50mg/kg once daily), administered by a nurse/doctor visiting once daily.
- Ward (Type: ACTIVE_COMPARATOR): Patients will be admitted to hospital ward and treated with six hourly flucloxacillin (50mg/kg), administered by a ward nurse as per routine practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).